Bladder cancer has the characteristics of multiple and easy recurrence after surgery.At present,the main treatment methods include surgery,chemotherapy,radiotherapy,and so on.However,the recurrence rate and metastasis rate are still very high,seriously threatening human health.Oncolytic viruses have become an important part of a comprehensive cancer treatment strategy.Compared with surgery,radiotherapy and chemotherapy,oncolytic virus therapy is more precise and less toxic,which is expected to significantly improve patients' quality of life.However,the therapeutic effects of oncolytic viruses alone are satisfactory.Currently,oncolytic viruses are combined with immunotherapy,chemotherapy or radiotherapy to improve the overall anti-tumor effects.The combination of oncolytic viruses and immunotherapy has a relatively broader prospect.This article reviews the research progress of the clinical application of adenovirus vectors,lentiviral vectors,adeno-associated virus vectors,and oncolytic viruses combined with immunotherapy,chemotherapy,and radiotherapy for bladder cancer.

Bladder cancer has the characteristics of multiple and easy recurrence after surgery.At present,the main treatment methods include surgery,chemotherapy,radiotherapy,and so on.However,the recurrence rate and metastasis rate are still very high,seriously threatening human health.Oncolytic viruses have become an important part of a comprehensive cancer treatment strategy.Compared with surgery,radiotherapy and chemotherapy,oncolytic virus therapy is more precise and less toxic,which is expected to significantly improve patients' quality of life.However,the therapeutic effects of oncolytic viruses alone are satisfactory.Currently,oncolytic viruses are combined with immunotherapy,chemotherapy or radiotherapy to improve the overall anti-tumor effects.The combination of oncolytic viruses and immunotherapy has a relatively broader prospect.This article reviews the research progress of the clinical application of adenovirus vectors,lentiviral vectors,adeno-associated virus vectors,and oncolytic viruses combined with immunotherapy,chemotherapy,and radiotherapy for bladder cancer.

Traditional endocrine drugs, such as bicalutamide, are the first choice for neoadjuvant therapy of prostate cancer. There are few reports on the use of new endocrine drugs in neoadjuvant therapy in China. The patient, male, 63 years old. He was admitted to the hospital for the finding of prostate space occupying. Blood PSA 53.50 ng / ml. Prostate MRI suggested that the prostate lesion broke through the left capsule, the left seminal vesicle gland was invaded, and the bladder wall was invaded. Bone scan suggested that: the left 8th posterior costal branch radioactivity was limited and increased. Prostate adenocarcinoma was diagnosed by puncture, Gleason score 4 + 4 = 8 points, and stage T 4bN 1M 1. The patient was treated with goserelin combined with enzalutamide for 3 months, and PSMA-PET CT: prostate size was normal, no significant 68Ga PSMA uptake was increased, no abnormally high Ga PSMA uptake in bones. The patient was treated with enzalutamide combined with ADT as neoadjuvant endocrine therapy, winning surgical conditions for the patient to undergo surgical resection.